Inhibitors of antiapoptotic mechanisms such as BCL2 (B-cell lymphoma 2) inhibitors are being tested in combination with other targeted therapies that modify tumor microenvironment and tumor mitochondrial energy metabolism in hematologic malignancies (detailed in (69)). The gene discussed is BCL2; the disease is neoplasm.